Sep 23 2026 10:13 PM EST

Apellis Shares Collapse as Biogen Integration and Guidance Cut Raise Debt Concerns

The market has driven Apellis Pharmaceuticals (NASDAQ: APLS) down roughly 92% over the past six months, reflecting a reassessment of the company’s post‑acquisition outlook, a cut to FY 2026 non‑GAAP EPS guidance and a rapidly expanding debt profile after the $5.6 billion merger with Biogen.

Biogen’s Q2 2026 filing disclosed that Syfovre contributed $97.4 million and Empaveli $30.4 million in recognized product revenue, boosting Biogen’s total product revenue to $1,916.4 million (+2% YoY). However, the combined contribution of $127.8 million was insufficient to offset a broader decline in Biogen’s legacy multiple‑sclerosis franchise, which fell 13% YoY. At the same time, total borrowings rose to $8.09 billion, a 28.7% increase YoY, while cash balances fell to $1.285 billion from $4.248 billion at year‑end 2025.

Acquisition Impact and Debt Profile

The March 31 2026 announcement to acquire Apellis for $41 per share added a non‑transferable contingent value right (CVR) of up to $4 per share tied to Syfovre sales through 2031. The cash consideration of roughly $5.6 billion was funded largely through new term‑loan facilities—$800 million (364‑day) and $1 billion (two‑year)—and the drawdown of an existing revolving credit facility, swelling total debt to over $8 billion. The higher leverage raises interest‑expense exposure and compresses the company’s interest‑coverage ratio to roughly 4.0× as of June 2026.

Guidance Revision and EPS Outlook

Biogen trimmed FY 2026 non‑GAAP diluted EPS guidance to a range of $12.00‑$13.00, down about $2.00 from the prior outlook. The reduction reflects roughly $3.00 per share of upfront IPR&D and milestone charges, plus a net operational dilution of $0.85 per share from the Apellis integration. Biogen expects the deal to become accretive to non‑GAAP EPS in FY 2027 after achieving its targeted $250 million annual run‑rate synergies.

Syfovre Sales Momentum and CVR Risk

Syfovre, the intravitreal pegcetacoplan approved for geographic atrophy, generated $587 million of U.S. net product revenue in FY 2025, representing about 60% of the GA market. While Q2 2026 saw a modest 8% YoY increase to $162 million, the broader market remains sensitive to pricing and gross‑to‑net pressures. The CVR tied to Syfovre sales could trigger a multi‑hundred‑million‑dollar cash outflow if the product reaches top‑tier thresholds, adding uncertainty to Biogen’s cash‑flow outlook.

Sector Context and Macro Tailwinds

The biotech sector has faced heightened volatility as investors demand clearer pathways to profitability. In Apellis’ case, the decline of Biogen’s multiple‑sclerosis franchise—down 13% YoY—highlights broader headwinds from generic competition and market saturation. Nonetheless, lower interest rates and a modestly improving credit environment have softened financing costs, a factor that partially offsets the debt burden introduced by the acquisition.

Pipeline Outlook and Competitive Position

Beyond Syfovre, Apellis retains Empaveli for paroxysmal nocturnal hemoglobinuria and recent label expansions into C3 glomerulopathy and immune‑complex‑mediated MPGN. Ongoing Phase 2 studies (APL‑3007 siRNA) and pivotal trials for Empaveli in FSGS and DGF are slated for late‑2025, while a preclinical FcRn editing program (APL‑9099) aims for IND filing in H2 2026. Competitors such as Alexion (Soliris) and Roche (Ravulizumab) continue to vie for complement‑inhibition markets, underscoring the importance of differentiation and pricing power for Apellis’ growth trajectory.

Risks and Uncertainties

Key risks include continued pressure on Syfovre pricing, the potential financial impact of the CVR, and the ability to achieve the targeted $250 million in synergies by FY 2027. Elevated leverage raises the stakes for cash‑flow generation, especially as cash balances have fallen by more than $3 billion since year‑end 2025. Additionally, post‑marketing safety signals of ischemic retinal vasculitis could prompt label revisions, and any delays in the upcoming pivotal trial readouts would further dampen investor sentiment.